Exact Sciences Corporation

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
44.57 ^USD	+3.20%		+5.49%	-39.75%

27/06	Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target	MT
26/06	BTIG Lowers Price Target on Exact Sciences to $70 From $80, Maintains Buy Rating	MT

Exact Sciences Corporation Provides Revenue Guidance for the Fourth Quarter of 2014

January 12, 2015 at 10:37 pm IST

Exact Sciences Corporation provided revenue guidance for the fourth quarter of 2014. The company estimates revenue during the fourth quarter of 2014 from Cologuard was approximately $1.5 million.

Latest news about Exact Sciences Corporation

Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target	27/06	MT
BTIG Lowers Price Target on Exact Sciences to $70 From $80, Maintains Buy Rating	26/06	MT
Exact Sciences Seeks Acquisitions	12/06	CI
Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM	12/06
Biocartis NV Appoints Gina Wallar as Chief Business Officer	10/06	CI
Transcript : Exact Sciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM	05/06
Transcript : Exact Sciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:40 PM	04/06
Exact Sciences Corporation Reaffirms Earnings Guidance for the Second-Quarter 2024 and Full-Year 2024	03/06	CI
Exact Sciences Corporation Announces Resignation of Everett Cunningham, Chief Commercial Officer, Effective on June 13, 2024	03/06	CI
Sector Update: Health Care Stocks Advance Pre-Bell Friday	24/05	MT
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test	24/05	MT
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®	24/05	CI
U.S. FDA advisers back approval for Guardant's cancer test	24/05	RE
Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed	21/05	MT
Transcript : Exact Sciences Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM	16/05
Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours	09/05	MT
Transcript : Exact Sciences Corporation, Q1 2024 Earnings Call, May 08, 2024	09/05
Earnings Flash (EXAS) EXACT SCIENCES Reports Q1 Revenue $637.5M, vs. Street Est of $626.8M	09/05	MT
Exact Sciences Corporation Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024	09/05	CI
Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024	09/05	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Exact Sciences Corporation Announces Board Resignations	26/04	CI
Exact Sciences Corporation announced that it has received $266.75 million in funding	17/04	CI
Sector Update: Health Care Stocks Advance Premarket Monday	15/04	MT
Exact Sciences Names Aaron Bloomer CFO	15/04	MT

Chart Exact Sciences Corporation

Duration

Period

More charts

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.

Sector

Biotechnology & Medical Research

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Exact Sciences Corporation

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.57 USD

Average target price

80.58 USD

Spread / Average Target

+80.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-39.75%	8.22B
GUARDANT HEALTH, INC.	+6.28%	3.52B
IOVANCE BIOTHERAPEUTICS, INC.	-10.46%	2.04B
BGI GENOMICS CO., LTD.	-27.73%	1.82B
VERACYTE, INC.	-21.74%	1.65B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+6.72%	928M
CAREDX, INC	+29.42%	811M
SEEGENE, INC.	-8.30%	702M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-27.76%	522M
CURIOX BIOSYSTEMS CO., LTD	-12.92%	255M

Bio Diagnostics & Testing